What prompted the switch to generic vascepa?

The switch to generic Vascepa, a prescription medication used to lower triglycerides, was prompted by the expiration of the drug's patent and the subsequent entry of generic competition into the market.

Vascepa, also known as icosapent ethyl, was approved by the US Food and Drug Administration (FDA) in 2012 as a treatment for high triglycerides [1]. The drug was developed by Amarin Pharmaceuticals and was marketed as a unique omega-3 fatty acid medication.

However, in 2019, the FDA approved the first generic version of Vascepa manufactured by Zand Pharma, Inc., a subsidiary of Alembic Pharmaceuticals [2]. This marked the beginning of generic competition in the Vascepa market.

The patent on Vascepa expired in 2023, allowing other pharmaceutical companies to develop and market their own generic versions of the medication [3]. Today, several generic versions of Vascepa are available in the US market, providing patients with more affordable treatment options for their triglyceride levels.

According to DrugPatentWatch.com, the expired US patent on Vascepa covers the period from 2023 until 2025 [4]. The expiration of the patent has led to increased competition in the market, which has driven down prices and made the medication more accessible to patients.

Sources:

[1] Drugs.com. (2023). Vascepa. Retrieved from https://www.drugs.com/vascepa.html

[2] FDA. (2019). Approved Generic of Vascepa. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-generic-vascepa

[3] PatentlyO. (2023). Patent Expiration – A Guide. Retrieved from https://patentlyo.com/patent/2023/02/patent-expiration-guide.html

[4] DrugPatentWatch.com. (2023). Vascepa Patent Expiration. Retrieved from https://www.drugpatentwatch.com/patent/expired/vascepa-icosapent-ethyl/